<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Affymetrix Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/affymetrix-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AFFX) Affymetrix&#8217;s Second Quarter Preliminary Sales Miss</title>
		<link>http://www.stockbloghub.com/2011/07/11/affx-affymetrixs-second-quarter-preliminary-sales-miss/78586</link>
		<comments>http://www.stockbloghub.com/2011/07/11/affx-affymetrixs-second-quarter-preliminary-sales-miss/78586#comments</comments>
		<pubDate>Mon, 11 Jul 2011 16:02:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78586</guid>
		<description><![CDATA[Genetic products maker Affymetrix Inc (AFFX) has announced disappointing preliminary sales for second-quarter fiscal 2011. The California-based company expects to post revenues in the band of $64-65 million for the quarter, which is below the current Street view of roughly $74 million. Affymetrix’s shares tanked $1.55 (or 19.4%) to $6.45 in after-hours trading on July 6. The company is expected to report final results for the second quarter after the closing gong on July 27. Affymetrix expects product sales for the quarter in the range of roughly $58-59 million, including consumable and instrument sales of approximately $55 million and $3.5 million, respectively. Service revenues are expected to be roughly $5 million while license and royalty revenues are expected inthe vicinity of $1 million. The company noted that its second quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/affx-affymetrixs-second-quarter-preliminary-sales-miss/78586/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Wraps Up EraGen Buy</title>
		<link>http://www.stockbloghub.com/2011/06/29/lmnx-luminex-wraps-up-eragen-buy/77787</link>
		<comments>http://www.stockbloghub.com/2011/06/29/lmnx-luminex-wraps-up-eragen-buy/77787#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:33:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77787</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has completed its previously-announced acquisition of privately-held diagnostic testing company EraGen Biosciences, Inc. for $34 million in cash. The companies struck a definitive agreement on June 21. Madison, Wisconsin-based EraGen, with annual sales of $8 million, makes molecular reagent products for infectious diseases and genetic-based conditions. The company’s products are based on its proprietary MultiCode technology platform. The acquisition provides Luminex a highly complementary portfolio of molecular diagnostic tests based on the MultiCode platform. Besides, it enables the company to tap new markets leveraging EraGen’s innovative technologies. Luminex envisions the acquisition to add between $5 million and $7 million to its sales for 2011. Moreover, the company expects the transaction to dilute its earnings (on a reported basis) in 2011 and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/lmnx-luminex-wraps-up-eragen-buy/77787/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Gets EraGen for $34M</title>
		<link>http://www.stockbloghub.com/2011/06/22/lmnx-luminex-gets-eragen-for-34m/77193</link>
		<comments>http://www.stockbloghub.com/2011/06/22/lmnx-luminex-gets-eragen-for-34m/77193#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:02:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77193</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has forged a definitive agreement to buy Madison, Wisconsin-based privately-held diagnostic testing company EraGen Biosciences, Inc. for $34 million in cash. The transaction, which is subject to the clearance of EraGen shareholders and other customary conditions, is expected to complete within the next few weeks. EraGen, with annual sales of $8 million, makes molecular reagent products for infectious diseases and genetic-based conditions. The company’s products are based on its proprietary MultiCode technology platform. EraGen received, in May 2010, the approval of the U.S. Food and Drug Administration (“FDA”) for its MultiCode-RTx HSV 1&#38;2 Kit. It is the first FDA-approved molecular test for the herpes simplex virus (“HSV”). The acquisition will provide Luminex a highly complementary portfolio of molecular diagnostic tests based ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/lmnx-luminex-gets-eragen-for-34m/77193/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFFX) Company News for June 03, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/03/affx-company-news-for-june-03-2011-corporate-summary/75495</link>
		<comments>http://www.stockbloghub.com/2011/06/03/affx-company-news-for-june-03-2011-corporate-summary/75495#comments</comments>
		<pubDate>Sat, 04 Jun 2011 05:03:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DeVry Inc.]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[DV]]></category>
		<category><![CDATA[EnergySolutions Inc]]></category>
		<category><![CDATA[ES]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Joy Global Inc.]]></category>
		<category><![CDATA[JOYG]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Sempra Energy]]></category>
		<category><![CDATA[SRE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75495</guid>
		<description><![CDATA[•    Joy Global Inc. (NASDAQ:JOYG) posted Q2 EPS of $1.52, higher than the Zacks Consensus Estimate of $1.35 per share. Revenue for the quarter grew 19% to $1.06 billion, beating the Zacks Consensus Estimate of $1.038 billion •    According to reports, Ford Motor Co (NYSE:F) is planning to invest around $100 million in robotic laser technology which will reduce wind noise inside vehicles •    Baird upgraded shares of Affymetrix, Inc. (NASDAQ:AFFX) to &#8220;Outperform&#8221; rating from &#8220;Neutral&#8221; rating, raising the target price to $11 from $6 •    Shares of Johnson &#38; Johnson (NYSE:JNJ) were upgraded by analysts of First Global to &#8220;Moderate Outperform&#8221; rating from &#8220;Market Perform&#8221; rating •    Analysts at BofA Merrill Lynch upgraded DeVry Inc. (NYSE:DV) to &#8220;Buy&#8221; rating from &#8220;Neutral&#8221; rating with a target price of $68 on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/03/affx-company-news-for-june-03-2011-corporate-summary/75495/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Tops Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741</link>
		<comments>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741#comments</comments>
		<pubDate>Thu, 12 May 2011 00:51:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73741</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, posted first-quarter fiscal 2011 earnings per share of 11 cents, comfortably beating the Zacks Consensus Estimate of 6 cents and exceeding the year-ago earnings of 5 cents. Profit more than doubled year over year to roughly $4.5 million owing to higher sales. Revenues shot up 30% year over year to $43.3 million, ahead of the Zacks Consensus Estimate of $40 million. The growth was led by solid consumables and assay sales. Consumable sales rocketed 53% to a record $15 million, buoyed by healthy demand from the company’s major partners. System revenues climbed 15% to $7.7 million, helped by healthy shipments of multiplexing analyzers. The Texas-based company shipped 197 analyzers (including 38 MAGPIX systems) in the quarter, flat year over year. Royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/11/lmnx-luminex-tops-earnings-estimates/73741/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFFX) Affymetrix Analyst Initiates Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708</link>
		<comments>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708#comments</comments>
		<pubDate>Sun, 17 Apr 2011 18:39:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[CBMX]]></category>
		<category><![CDATA[CombiMatrix Corporation]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71708</guid>
		<description><![CDATA[We initiate our coverage on genetic products maker Affymetrix (AFFX) with a Neutral recommendation. The company posted respectable results in fourth-quarter fiscal 2010 with earnings beating the Zacks Consensus Estimate while profit surged 42% year over year as lower costs more than offset a decline in sales. California-based Affymetrix is a leading provider of microarray-based products and services to the global research community. Along with Illumina Inc. (ILMN), it is one of the two major providers of microarray technologies primarily used in the field of genetic research. Affymetrix has expertise in gene expression monitoring arrays, which are used to identify correlations between genes, determine their biological functions, and identify patterns that enable more accurate disease classification. It has a dominant position in the gene expression market and enjoys a recurring ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/17/affx-affymetrix-analyst-initiates-shares-at-neutral/71708/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFFX) Affymetrix Intros New Axiom Array</title>
		<link>http://www.stockbloghub.com/2011/04/13/affx-affymetrix-intros-new-axiom-array/71480</link>
		<comments>http://www.stockbloghub.com/2011/04/13/affx-affymetrix-intros-new-axiom-array/71480#comments</comments>
		<pubDate>Thu, 14 Apr 2011 02:30:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71480</guid>
		<description><![CDATA[Genetic products maker Affymetrix Inc (AFFX) has broadened its Axiom Genotyping Solution (a high-throughput genotyping platform) with the launch of the Axiom Genome-Wide CHB 1 Array. It is the first commercial product designed to maximize genetic coverage of common alleles (an allele is one of a pair or series of genes) in the Han Chinese population. The Genome-Wide CHB 1 Array will offer researchers a powerful and cost-effective tool for studying disease and characterizing the genetic basis of the disease in the Han Chinese population. The Han Chinese are an ethnic group representing roughly 92% of the overall Chinese population. Genome-Wide CHB 1 represents the company’s third population-designed array for the Axiom Genotyping Solution platform. It has the highest coverage of variants in important biological categories compared with other arrays ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/affx-affymetrix-intros-new-axiom-array/71480/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex MAGPIX Wins MDEA</title>
		<link>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348</link>
		<comments>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348#comments</comments>
		<pubDate>Wed, 13 Apr 2011 17:12:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71348</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, recently received the prestigious Medical Design Excellence Award (“MDEA”) for its MAGPIX analytical instrument. MDEA, organized by the leading business-to-business media company UBM Canon, is a premier awards program which recognizes the achievements of medical devices manufacturers. MAGPIX was recognized in the “In Vitro Diagnostics” category of the award, through a comprehensive review by a multi-disciplinary jury panel, for its innovative design and contribution. The award will be presented at a ceremony on June 8, 2011, at the Jacob K. Javits Convention Center in New York City. The MAGPIX system (launched in July 2010) leverages Luminex’s proprietary open-architecture xMAP technology and is capable of producing up to 50 tests on a single sample. The versatile multiplexing platform can be used to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/lmnx-luminex-magpix-wins-mdea/71348/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Earns FDA Approval for New Diagnostic Test</title>
		<link>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911</link>
		<comments>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911#comments</comments>
		<pubDate>Thu, 18 Nov 2010 19:00:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[China Petroleum & Chemical Corporation]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SNP]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59911</guid>
		<description><![CDATA[Luminex Corporation (LMNX), a developer of biological testing technologies, has commenced the commercial launch of its first pharmacogenetic test following its recent approval by the U.S. Food and Drug Administration (FDA). Pharmacogenetics is the study of genetic factors that influence an individual&#8217;s response to drugs. The test, dubbed the xTAG CYP2D6 Kit, has been designed to bring in the personalized medicine approach by helping physicians to identify and manage patients for whom they may prescribe therapies which are metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme. The xTAG CYP2D6 Kit will be marketed throughout the U.S. through Luminex Molecular Diagnostics (“LMD”), a unit of the company’s Assay segment. The CYP2D6 enzyme is involved in the metabolism of many prescription drugs. A segment of the population may carry a slow-acting or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/18/lmnx-luminex-earns-fda-approval-for-new-diagnostic-test/59911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442</link>
		<comments>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442#comments</comments>
		<pubDate>Tue, 16 Nov 2010 04:50:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59442</guid>
		<description><![CDATA[We downgrade our recommendation on Luminex Corporation (LMNX) to Underperform following the company’s lower-than-expected third quarter results and a less favorable outlook. Third-quarter fiscal 2010 adjusted loss per share of 2 cents missed the Zacks Consensus Estimate of earnings of 4 cents. Losses swelled 19% year over year as revenue growth was offset by higher costs and tax. Top line improved on solid consumables and assay sales, but missed the Zacks Consensus Estimate. Annualized decline in the shipments of analytical instruments contributed to lower system sales in the quarter.The company has narrowed its revenue forecast for fiscal 2010. Luminex develops, manufactures and markets proprietary biological testing technologies, which have applications across the life sciences industry. The company’s proprietary open-architecture xMAP technology enables fast, cost-effective and accurate conduct and analysis of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/lmnx-luminex-analyst-downgrades-shares-to-underperform/59442/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DCTH) The Decade of Biotech: Two Hot Biotech Sectors and Eight Ways to Profit</title>
		<link>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446</link>
		<comments>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:13:04 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35446</guid>
		<description><![CDATA[I expect the 2010s to be the “Decade of Biotech.” In 2020, we’ll look back at the past 10 years in amazement at how many medical advances were achieved. And we’ll likely snicker at some of the prehistoric methods that are currently used, equating them to when doctors used to perform lobotomies on people with mental problems. By 2020, there will be new drugs on the market and technologies developed that weren’t even dreamed about at the turn of the 21st century. New discoveries will extend life, or cure diseases that even the most forward-thinking scientists couldn’t have imagined just a short time ago. And fortunes will be made as a result. The question is: How do you grab your piece of the pie? Blasting Tumors… Bagging Profits If you’re ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation Upgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199</link>
		<comments>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:15:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25199</guid>
		<description><![CDATA[Recently, we upgraded Luminex Corp. (LMNX) to Neutral from Underperform. Our decision to upgrade the stock was based on the company’s wide range of products and its significant international presence. These positive factors should drive growth in the coming quarters. Additionally, Luminex has an interesting pipeline. Should the pipeline develop successfully, the company can look at further growth. We are pleased with the company&#8217;s broad product portfolio. Luminex’s instrument base consists of the Luminex 100 (LX100), Luminex 200 (LX200) and FlexMap 3D systems. The Luminex 100 and 200 are compact analyzers that integrate fluidics, optics and digital signal processing to perform up to 100 bioassays simultaneously in a single tube or well of a microtiter plate using only a small amount of sample. By combining small diode lasers with digital ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/lmnx-luminex-corporation-upgraded-to-neutral/25199/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corporation Posts Loss</title>
		<link>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552</link>
		<comments>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552#comments</comments>
		<pubDate>Tue, 01 Dec 2009 00:36:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[Sequenom Inc]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21552</guid>
		<description><![CDATA[Luminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or 1 cent per share as opposed to a net income of $3.2 million or 8 cents in the comparable period of 2008. The Zacks Consensus Estimate for the reported quarter was a gain of 7 cents. The loss in the quarter was attributable to the higher operating expenses which more than offset the increase in revenues. Total revenues for the reported quarter came in at $29.1 million as against $28.9 million in the year-ago period, up 1%. As per segments, revenues from the Technology segment came in at 22 million as against $22.6 million in the year-ago quarter. Assay group sales for the quarter came in at approximately $7.1 million, up 12% over the comparable quarter of 2008. Total ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/30/lmnx-luminex-corporation-posts-loss/21552/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

